Exploring the performance of Multifactor Dimensionality Reduction in large scale SNP studies and in the presence of genetic heterogeneity among epistatic disease models.
about
Considerations for using genetic and epigenetic information in occupational health risk assessment and standard settingBridging the gap between statistical and biological epistasis in Alzheimer's diseaseAssociation between risk of oral precancer and genetic variations in microRNA and related processing genes.Detecting purely epistatic multi-locus interactions by an omnibus permutation test on ensembles of two-locus analyses.A general framework for formal tests of interaction after exhaustive search methods with applications to MDR and MDR-PDT.An omnibus permutation test on ensembles of two-locus analyses can detect pure epistasis and genetic heterogeneity in genome-wide association studies.Survival dimensionality reduction (SDR): development and clinical application of an innovative approach to detect epistasis in presence of right-censored data.Methods for investigating gene-environment interactions in candidate pathway and genome-wide association studies.A comparison of internal model validation methods for multifactor dimensionality reduction in the case of genetic heterogeneity.Vitamin D receptor gene as a candidate gene for Parkinson disease.Pharmacogenomics of long-acting β2-agonists.Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.Multifactor dimensionality reduction as a filter-based approach for genome wide association studies.A screening methodology based on Random Forests to improve the detection of gene-gene interactions.Predicting the difficulty of pure, strict, epistatic models: metrics for simulated model selection.Role of genetic heterogeneity and epistasis in bladder cancer susceptibility and outcome: a learning classifier system approach.Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.Genetics of Alzheimer's disease
P2860
Q23919015-E6D36F12-5C4A-4839-9AF6-930BD642EDC3Q27022673-C2FC62AE-1A47-4DCA-88F2-3F45999A6203Q30487016-DC233553-C642-4864-A92B-675292410705Q33504429-B535E1A7-7366-44D1-9BA8-7A44D356E5B6Q33534676-E66B3305-B480-4535-8E39-9A718B177C35Q33552149-979576E9-3BF8-4778-A144-A91556184505Q33651708-B02BA530-ED85-47B1-BF0D-BCAE0A82A1A1Q33761835-3EBFCDDA-80B8-4F20-B41F-BAB6D37593CEQ34309985-158DFEBF-4CB9-4A28-BD1D-A14CF1D046AFQ34796120-612CDCC0-B258-4388-9AFE-77F9C6E11320Q35734012-5737CBE6-D368-44B0-826E-CEAFF393253FQ38285850-922DA316-CF7D-45CB-A394-63EF3721EAF3Q40740062-4D0B7F3D-9FAE-40D9-ADCB-EB769D85B982Q41733505-BA342D8A-2A93-4AFD-AE9D-4C4107743B88Q42025008-34931D6A-14B9-4C10-8E35-3CE4D1C9014BQ43077589-FECE17B9-4154-4872-A839-578F90ABE681Q54180020-00DB486A-5A10-433B-8BA8-2712A8C5537EQ58920538-B5F43909-1922-4763-B2EA-ED1BBFC4166D
P2860
Exploring the performance of Multifactor Dimensionality Reduction in large scale SNP studies and in the presence of genetic heterogeneity among epistatic disease models.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Exploring the performance of M ...... mong epistatic disease models.
@en
type
label
Exploring the performance of M ...... mong epistatic disease models.
@en
prefLabel
Exploring the performance of M ...... mong epistatic disease models.
@en
P2093
P2860
P356
P1433
P1476
Exploring the performance of M ...... mong epistatic disease models.
@en
P2093
Digna R Velez
Kenneth Lewis
Scott Dudek
Todd L Edwards
P2860
P304
P356
10.1159/000181157
P577
2008-12-15T00:00:00Z